RNID Hearing Therapeutics Summit 2025

RNID are excited to invite you to their Hearing Therapeutics Summit 2025 – a bi-annual event focused on bringing the research sector together to advance the development of novel therapeutics for hearing loss and tinnitus. This event is an excellent opportunity to engage with leading experts, share research updates, and connect with peers from around the world and across sectors.

Date: Thursday 13 November 2025

Location: 1 Wimpole Street, London, W1G 0AE

Highlights of the Summit:

Engaging speakers: Hear from key opinion leaders, industry experts, innovators and people with lived experience.
Panel discussions: Participate in dynamic conversations on current challenges and opportunities relevant to the field.
Research updates: Discover the latest findings from across the preclinic and clinical development landscapes.
Networking opportunities: Connect with academic researchers, key opinion leaders and industry professionals.

Whether you are looking to gain new insights, expand your professional network or increase your understanding of the field, RNID’s Hearing Therapeutics Summit offers a unique opportunity to achieve this.

Registration Information:

Visit RNID’s Summit webpage to secure your spot and learn more about the summit agenda, speakers, and sessions.
Don’t miss this chance to be part of this engaging specialist event. RNID look forward to welcoming you.

13 November 2025

Find out more

Let us know you are attending

Dr Beverley Isherwood

Partnership Lead

Beverley has responsibility for setting up and providing strategic and scientific leadership and direction for MDC’s infectious disease Syndicate portfolio, including the CF AMR Syndicate.

Bev has extensive experience in the development and delivery of collaborative research consortia bringing together experts from different sectors to shape research agendas and drive research efforts focused on unmet needs including working with and supporting SMEs who are developing the next generation of medicines for patients. The current focus is on shaping an ecosystem of partnerships in Infectious Disease working with colleagues internally and across the sector to help accelerate medicines development in this area.

MDC representative on the cross-Catapult Research and Technology Group. Bev has extensive experience in drug discovery across a broad range of disease indications and therapeutic modalities having previously held leadership roles in the biopharmaceutical industry. Bev is an Associate Editor for SLAS Discovery, and holds an MA (Natural Sciences) from Cambridge University and a PhD in Molecular Virology from the MRC-University of Glasgow Centre for Virus Research. Member of the Association of Strategic Alliance Professionals with CA-AM accreditation.